NORTHX BIOLOGICS MATFORS AB

Their core work

NorthX Biologics is a Swedish contract development and manufacturing organization (CDMO) specializing in advanced biopharmaceuticals, with deep expertise in bioprocess development for gene therapies, cell therapies, oncolytic viruses, and therapeutic proteins. They provide GMP-capable manufacturing infrastructure for complex biologics that require specialized production processes beyond standard pharmaceutical factories. In H2020, they contributed as an industrial host in a doctoral training network for upstream bioprocess development, and later joined a COVID-19 rapid vaccine/therapy platform initiative — both roles consistent with a CDMO that bridges academic research and clinical-scale production. For potential partners, NorthX brings hands-on manufacturing know-how and analytical capabilities (mass spectrometry, next-generation sequencing, single cell analysis) that most academic or early-stage biotech partners lack.

What they specialise in

How they've shifted over time

NorthX entered H2020 through STACCATO (2019–2022), a Marie Skłodowska-Curie industrial doctorate focused on upstream bioprocess development for a broad range of advanced biologics — gene therapies, cell therapies, oncolytic viruses, and therapeutic proteins. Their early profile is that of a specialized CDMO providing industrial training and manufacturing context for academic researchers. By 2020, their second project (OPENCORONA) shifted focus sharply toward infectious disease response, specifically COVID-19 vaccine and therapy platforms, reflecting both market demand and the organization's pivot toward pandemic-relevant manufacturing capabilities.

NorthX is moving from a broad CDMO identity toward infectious disease and vaccine manufacturing, suggesting future consortia around pandemic preparedness, mRNA or viral vector platforms, or rapid-response biomanufacturing would be a natural fit.

How they like to work

NorthX consistently joins projects as a partner or participant rather than taking a coordinator role, which is typical for CDMOs whose value lies in manufacturing execution rather than project management. Their participation in an MSCA industrial doctorate (STACCATO) shows willingness to support research training within a large multi-partner consortium — a sign of openness to academic collaboration. With 21 unique partners across 8 countries from just 2 projects, they clearly operate in diverse international consortia rather than a closed network.

NorthX has accumulated 21 unique consortium partners across 8 countries from only 2 projects, indicating they joined large, internationally distributed consortia. Their network spans multiple European countries, consistent with pan-European biotech and pharma collaboration patterns.

What sets them apart

NorthX Biologics is one of relatively few Nordic SME CDMOs with documented H2020 participation in both advanced therapy manufacturing (ATMPs) and infectious disease vaccine development — a rare dual capability. As a Swedish GMP-capable facility with bioanalytical depth (NGS, mass spectrometry), they fill the gap between academic research partners and large pharmaceutical manufacturers in consortia building for clinical translation. For a consortium that needs a credible industrial manufacturing partner without the overhead or rigidity of a large pharma company, NorthX offers a pragmatic middle ground.

Highlights from their portfolio

• OPENCORONA
  Secured EUR 1.2M in EC funding for rapid COVID-19 vaccine and therapy platform development, demonstrating NorthX's ability to mobilize manufacturing capacity for pandemic-scale urgent response.
• STACCATO
  Participation as an industrial host in a European Industrial Doctorate (MSCA-ITN) signals NorthX's role as a training-capable CDMO bridging academic bioprocess research and GMP manufacturing practice.